Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial
This prospective, multicenter, community‐based and academic‐based, open‐label, investigator‐initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG‐IFN) alfa‐2b plus a flat or weight‐based dose of ribavirin (RBV) in adults with chronic hepatitis C. Patients (n = 5027) were r...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2007-10, Vol.46 (4), p.971-981 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | This prospective, multicenter, community‐based and academic‐based, open‐label, investigator‐initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG‐IFN) alfa‐2b plus a flat or weight‐based dose of ribavirin (RBV) in adults with chronic hepatitis C. Patients (n = 5027) were randomly assigned to receive PEG‐IFN alfa‐2b 1.5 μg/kg/week plus flat‐dose (800 mg/day) or weight‐based (800‐1400 mg/day) RBV for 48 weeks (patients with genotype 1, 4, 5, or 6) and for 24 or 48 weeks (genotype 2/3 patients). Primary end point was sustained virologic response (undetectable [ |
---|---|
ISSN: | 0270-9139 1527-3350 |
DOI: | 10.1002/hep.21932 |